Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.

  PMID 33086062 · PMC7649750 · Cell reports · 2020 · 8 claims · 8 setups

  Has reproduction · 59

  KMT2D is a potent tumor suppressor in melanoma

  hmel-brafv600e tyr-creert2 tma kmt2d pooled xenograft genetically

• Disruption of tRNA threonylation triggers RIG-I mediated anti-tumour immune response.

  PMID 41735308 · PMC13043769 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  OSGEP is the catalytic subunit of the KEOPS complex responsible for t6A modification at position 37 of cytoplasmic tRNAs, and its loss causes the highest protein aggregation among 45 screened tRNA-modifying enzymes in melanoma cells

  mm117 b16f10 b16f10-derived c57bl esirna shrna rna-seq

• Proteomic and genetic approaches identify Syk as an AML target.

  PMID 19800574 · PMC2803063 · Cancer cell · 2009 · 8 claims · 8 setups

  Full-text index only

  EGFR inhibitors (e.g., gefitinib) induce AML differentiation through a non-EGFR, off-target mechanism

  hl-60 aml molm-14 luciferase-labeled phospho-tyrosine kinome-wide secondary

• VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING.

  PMID 41820368 · PMC13121600 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  CBFB (CBF-β) is a synthetic lethal interactor of VHL in ccRCC cell lines

  786o ccrcc tcga genome-wide competitive immunoblot